Connection
Christine McMahon to Protein Kinase Inhibitors
This is a "connection" page, showing publications Christine McMahon has written about Protein Kinase Inhibitors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.599 |
|
|
|
-
McMahon CM, Ferng T, Canaani J, Wang ES, Morrissette JJD, Eastburn DJ, Pellegrino M, Durruthy-Durruthy R, Watt CD, Asthana S, Lasater EA, DeFilippis R, Peretz CAC, McGary LHF, Deihimi S, Logan AC, Luger SM, Shah NP, Carroll M, Smith CC, Perl AE. Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia. Cancer Discov. 2019 08; 9(8):1050-1063.
Score: 0.401
-
McMahon CM, Perl AE. Gilteritinib for the treatment of relapsed and/or refractory FLT3-mutated acute myeloid leukemia. Expert Rev Clin Pharmacol. 2019 Sep; 12(9):841-849.
Score: 0.102
-
McMahon CM, Luger SM. Maintenance therapy in acute myeloid leukemia: What is the future? Semin Hematol. 2019 04; 56(2):102-109.
Score: 0.095